$BMY News

What Does Bristol Myers Squibb (BMY) Zola Cel MS Trial Update Mean?

Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors

Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

The Call Bristol-Myers Squibb Bulls Got Right

Bristol Myers Squibb (BMY) Bets On AI Drug Discovery And Wider Trial Access

Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know

BMY Stock Falls 2% After Patient Death In Early Multiple Sclerosis CAR T Trial

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026

What's Going On with Bristol Myers Squibb Stock on Friday?

Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At MS Toronto Occurred After Trial Pause; Working Closely With FDA To Restart Trial As Soon As Possible, With The Goal Of Resuming Enrollment In Early 2027; Grade 5 Event That Was Disclosed Was Not Related To Our Decision To Pause The BreakFree Program

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

Bristol Myers Squibb Presents Interim Safety, Efficacy Data From Its Multiple Sclerosis Groups Of Phase 1 Trial Of Zolacabtagene Autoleucel At MSToronto 2026

Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?

SystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026

Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue

IHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials